In this open-label randomised , two-by-two factorial phase 3 study in 185 institutions in the USA and Canada , we enrolled patients ( aged 18 years ) with unresectable stage III non-small-cell lung cancer , a Zubrod performance status of 0-1 , adequate pulmonary function , and no evidence of supraclavicular or contralateral hilar adenopathy .